Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-05-06
- Target Recruit Count
- 28
- Registration Number
- NCT06760156
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-05-06
- Target Recruit Count
- 318
- Registration Number
- NCT06745882
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening
- Conditions
- Colorectal Cancer ScreeningHepatitis C Virus
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 350
- Registration Number
- NCT06745895
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
- Conditions
- Metastatic Castration Sensitive Prostate Cancer
- Interventions
- Drug: Luteinizing Hormone-Releasing Hormone (LHRH) analogDrug: Androgen Receptor Signal Inhibitor (ARSI)
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-03-17
- Target Recruit Count
- 25
- Registration Number
- NCT06734130
- Locations
- 🇺🇸
Moffitt Caner Center, Tampa, Florida, United States
Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center
- Conditions
- Pancreatic Ductal AdenocarcinomaIntraductal Papillary Mucinous Neoplasm
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2025-05-07
- Target Recruit Count
- 24
- Registration Number
- NCT06712797
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Digoxin Medulloblastoma Study
- Conditions
- MedulloblastomaMedulloblastoma, Non-WNT/Non-SHH
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2025-04-22
- Target Recruit Count
- 23
- Registration Number
- NCT06701812
- Locations
- 🇺🇸
University of Alabama at Birmingham Children's of Alabama, Birmingham, Alabama, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Johns Hopkins All Children's, Saint Petersburg, Florida, United States
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
- Conditions
- Breast Cancer Metastatic Breast CancerHER2-negative Breast Cancer
- Interventions
- Biological: DC1 native/mutated ESR1
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2025-05-07
- Target Recruit Count
- 18
- Registration Number
- NCT06691035
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Interventions
- Drug: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-03-17
- Target Recruit Count
- 52
- Registration Number
- NCT06660368
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
- Conditions
- Chronic Graft-versus-host Disease (cGVHD)
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-03-17
- Target Recruit Count
- 120
- Registration Number
- NCT06660355
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 43
- Registration Number
- NCT06597565
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States